Skip to main content
Toggle navigation
Login
Home
Back
Favorite
0
Like
Facebook
Tweet
Session III: Urothelial Cancer
Debate: Cisplatin-Ineligible Patient with Advanced Urothelial Cancer with LN-only Metastasis and PD-L1 High Tumor - Pembrolizumab
Wednesday, March 9, 2022
2:22 PM – 2:29 PM
Debate Speaker(s)
Peter H. O'Donnell, MD
The University of Chicago